AstraZeneca PLC (AZN)

8,411.0
-97.0(-1.14%)
  • Volume:
    1,748,231
  • Bid/Ask:
    8,300.0/9,120.0
  • Day's Range:
    8,344.0 - 8,560.0

AZN Overview

Prev. Close
8,508
Day's Range
8,344-8,560
Revenue
24.4B
Open
8,383
52 wk Range
6,499.8-9,523
EPS
0.95
Volume
1,748,231
Market Cap
130.3B
Dividend (Yield)
202.20
(2.38%)
Average Vol. (3m)
1,790,586
P/E Ratio
89.45
Beta
0.35
1-Year Change
9.08%
Shares Outstanding
1,549,146,845
Next Earnings Date
Feb 11, 2022
What is your sentiment on AstraZeneca PLC?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC Company Profile

Employees
76100

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • unvaccinated ban they can not longer eat in shopping malls or market
    0
    • thanks for destroying the lives of a milliard of families with your vaccine but your money are well
      0
      • An attractive PRE-IPO called SpectrumX based in England plans to launch by November and i'm very hopeful of this particular investment. Clinical trials for their Covid-19 respiratory treatment are now in phase 2 of development which will be a game changer once hospitals get their hands on it. This will not be factored into the company valuation when listed. So if the trials are successful the market value will rocket. Thats why im seriously excited about this IPO and i don't usually go near PRE IPO's.
        4
        • 50
          0
          • *50000
            0
        • 19970410🌍 10000%
          0
          • Most of vunerable demographic now vaccinated. Will younger people accept the jab or will potential health concerns outweigh the potential benefits. I'm short AstraZeneca
            4
            • net short positions available on the PNC Borsa app
              0
              • Above 7500 to 9750 soon these weeks bullish sentiments business development infrastructure expenditures stimulus package cause its stance growth economics of scales
                2
                • you are nostetadamoos
                  1
              • may be buy or sell the stock but be very cautious before being vaccinated : some serious cases in Europe especially with young to intermediate people
                10
                • GP GAPYes Im chief nurse teacher in a very big hospital. Not specialised in vaccine but i know a little bit about heath. And im a pro vaccine. But the rule we were givenby health autorities  was : Astra not for people under 55.
                  1
                • Thanks for the advise.
                  0
                • Jenny Goughlike dada
                  0
              • This is moving now....at last! US approval coming.
                1
                • The cause behind the suspected vaccine side effects has been found. This is the opinion of a Norwegian expert group that examined the three healthcare employees who were admitted to hospital after being vaccinated with Astra Zeneca's vaccine. The vaccine triggered a strong immune reaction in the people. - I see no other reason than that it is the vaccine that triggers it, says the chief physician and professor Pål Andre Holme to VG. Sell off coming
                  5
                  • I guess that puts this Professor at odds with all the others looking at the data then.   Strange they were all healthcare employees.
                    0
                  • u shorting?
                    1
                • AZN will go up & up
                  2
                  • Up today due to the £700m+ from disposal; vaccine is fine - EU politics.   Also good for those on kidney dialysis like a member of my family who can have this vaccine (& who has no ill effects). Only not for profit as long as pandemic is declared as one - but everyone likely to need annual jabs after that... great company.
                    0
                    • buy guys world health organization is giving advice to buy astrazeneca , you guys dum enough?
                      2
                      • Don't buyyyyyyy!!!!!
                        6
                        • Ive had the vaccine. It was great): All mainstream drug companies suffering as hospitals taken over with covid and thus everything else delayed and postponed.  Backlog will have to be caught up...  Also AZ only free for duration of pandemic... wont always be a pandemic but will likely need annual vaccines...  Hold but forget about it for a bit.
                          7
                          • So much good news today why it is going down oO
                            1
                            • What a *****stock! So disappointing!
                              0
                          • Good info about vaccine acceptancy
                            0
                            • It looks like purchasing volume are getting interesting....
                              0
                              • 11/02 earnings before market.
                                0
                                • how much possible drop after?
                                  0
                              • good for long term
                                0
                                • Ruin that trash, because of that trash whole markate crashing.
                                  4
                                  • Naked Brand stock 🚀
                                    2
                                    • it has started to roll :)
                                      1
                                      • finaly
                                        0
                                    • 8.000-8.100£
                                      1
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.